Consistently, several DYRK1A inhibitors have demonstrated promising results in rescuing the Aβ and NFTs phenotypes in various in vivo models of AD (Kim et al., 2016; Melchior et al., 2019; Velazquez et al., 2019; Stensen et al., 2021; Zhu et al., 2022; Grygier et al., 2023; Liu et al., 2023). The gene discussed is DYRK1A; the disease is Alzheimer disease.